Fabrice André

Fabrice André

UNVERIFIED PROFILE

Are you Fabrice André?   Register this Author

Register author
Fabrice André

Fabrice André

Publications by authors named "Fabrice André"

Are you Fabrice André?   Register this Author

100Publications

5100Reads

14Profile Views

Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future.

Lancet 2020 03;395(10226):817-827

Department of Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(20)30165-3DOI Listing
March 2020

Genomic Alteration in Metastatic Breast Cancer and Its Treatment.

Am Soc Clin Oncol Educ Book 2020 Mar;40:1-14

Department of Hematology Oncology, Oregon Health & Science University, Knight Cancer Institute, Portland, OR.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_280463DOI Listing
March 2020

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.

N Engl J Med 2020 02 11;382(7):610-621. Epub 2019 Dec 11.

From Memorial Sloan Kettering Cancer Center, New York (S.M.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona (C.S., J.C.), and IOB Institute of Oncology, Quiron Group, Barcelona and Madrid (J.C.); Kanagawa Cancer Center, Yokohama (T.Y.), National Cancer Center Hospital (K.T.), the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (Y.I.), and the Advanced Cancer Translational Research Institute, Showa University (J.T.), Tokyo, Aichi Cancer Center Hospital, Nagoya (H.I.), Kindai University Faculty of Medicine, Osaka (J.T.), Shikoku Cancer Center, Matsuyama (K.A.), and the National Hospital Organization Kyushu Cancer Center, Fukuoka (E.T.) - all in Japan; Samsung Medical Center (Y.H.P.), Asan Medical Center, University of Ulsan College of Medicine (S.-B.K.), Yonsei Cancer Center, Yonsei University Health System (J. Sohn), and Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), Seoul, and the National Cancer Center, Gyeonggi (K.S.L.) - all in South Korea; Institut Gustave Roussy, Université Paris-Sud, Villejuif (F.A.), and Centre Eugène Marquis, Rennes (C.P.) - both in France; the US Oncology Network, Virginia Cancer Specialists, Arlington (N.D.); the University of California, Los Angeles-Jonsson Comprehensive Cancer Center, Los Angeles (S.A.H.); Daiichi Sankyo, Basking Ridge, NJ (C.L., S.C., L.Z., J. Shahidi, A.Y.); and the Dana-Farber Cancer Institute, Boston (I.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1914510DOI Listing
February 2020

Reply to A. Katz.

J Clin Oncol 2020 Jan 1;38(1):102-103. Epub 2019 Nov 1.

N. Lynn Henry, MD, PhD, University of Michigan, Ann Arbor, MI; Fabrice Andre, MD, PhD, Institute Gustave Roussy, Paris Sud University, Paris, France; Nofisat Ismaila, MD; Mark R. Somerfield, PhD, American Society of Clinical Oncology, Alexandria, VA; and Vered Stearns, MD, Johns Hopkins University School of Medicine, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.02431DOI Listing
January 2020

Alpelisib for PIK3CA-Mutated Advanced Breast Cancer. Reply.

N Engl J Med 2019 08;381(7):687

Novartis Pharmaceuticals, East Hanover, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1907856DOI Listing
August 2019

Targeting TCTP with Sertraline and Thioridazine in Cancer Treatment.

Results Probl Cell Differ 2017;64:283-290

Bâtiment B2M, Institut Gustave Roussy, Unité Inserm U981, 114 rue Édouard-Vaillant, 94805, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-67591-6_15DOI Listing
July 2019

Fatigue and physical activity in cancer survivors: A cross-sectional population-based study.

Cancer Med 2019 05 12;8(5):2535-2544. Epub 2019 Mar 12.

Department of Medical Oncology, Gustave Roussy, Université Paris-Sud, Université Paris-Saclay, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.2060DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536944PMC
May 2019

Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer.

N Engl J Med 2019 05;380(20):1929-1940

From Institut Gustave Roussy, INSERM Unité 981, Université Paris-Sud, Villejuif (F.A.), Institut de Cancérologie de l'Ouest, St. Herblain (M.C.), and Novartis Pharma, Paris (A.-S.L.) - all in France; Hospital Universitario 12 de Octubre, Madrid (E.C.); National Institute of Oncology (G.R.) and Duna Medical Center (Z.P.), Budapest, Hungary; German Breast Group, Neu-Isenburg, and Center for Hematology and Oncology Bethanien, Frankfurt - both in Germany (S.L.); UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco (H.S.R.); Aichi Cancer Center, Nagoya (H.I.), Kanagawa Cancer Center, Yokohama (T.Y.), Saitama Cancer Center, Saitama (K.I.), and National Hospital Organization Hokkaido Cancer Center, Sapporo (M.T.) - all in Japan; Istituto Oncologico Veneto and the Departments of Surgery, Oncology, and Gastroenterology, University of Padua, Padua, Italy (P.C.); Vanderbilt University, Nashville (I.A.M.); Chaim Sheba Medical Center, Tel Hashomer, Israel (B.K.); National Taiwan University Hospital, Taipei (Y.-S.L.); Novartis Pharma, Basel, Switzerland (D.M., C.W.); Novartis Pharmaceuticals, East Hanover, NJ (S.H.); and Massachusetts General Hospital Cancer Center, Boston (D.J.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1813904
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1813904DOI Listing
May 2019

News from the San Antonio Breast Cancer Symposium 2018.

Breast Care (Basel) 2019 Mar 13;14(1):60-62. Epub 2019 Feb 13.

Klinik für Gynäkologie und Geburtshilfe, Helios Klinikum Berlin-Buch, Berlin, Germany.

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/497371
Publisher Site
http://dx.doi.org/10.1159/000497371DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6465690PMC
March 2019

American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange: From Inception to First Data Release and Beyond-Lessons Learned and Member Institutions' Perspectives.

JCO Clin Cancer Inform 2018 12;2:1-14

Christine M. Micheel, Michele L. LeNoue-Newton, and Mia A. Levy, Vanderbilt University Medical Center, Nashville, TN; Shawn M. Sweeney, American Association for Cancer Research, Philadelphia, PA; Fabrice André, Institut Gustave Roussy, Villejuif, France; Philippe L. Bedard, University of Toronto, Toronto, Ontario, Canada; Justin Guinney, Sage Bionetworks, Seattle, WA; Gerrit A. Meijer, Netherlands Cancer Institute, Amsterdam, the Netherlands; Barrett J. Rollins, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA; Charles L. Sawyers and Nikolaus Schultz, Memorial Sloan Kettering Cancer Center, New York, NY; Charles L. Sawyers, Howard Hughes Medical Institute, Chevy Chase, MD; Victor E. Velculescu, Johns Hopkins University School of Medicine, Baltimore, MD; and Kenna R. Mills Shaw, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/CCI.17.00083DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6873906PMC
December 2018

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.

N Engl J Med 2018 Nov 20;379(20):1926-1936. Epub 2018 Oct 20.

From the Institute of Cancer Research and Royal Marsden Hospital, London (N.C.T.); David Geffen School of Medicine at University of California, Los Angeles, Santa Monica (D.J.S.), and Pfizer Oncology, San Diego (X.H.) - both in California; National Cancer Center, Goyang-si, Gyeonggi-do (J.R.), and Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul (S.-A.I.) - both in South Korea; Dnipropetrovsk Medical Academy, City Multiple-Discipline Clinical Hospital 4, Dnipropetrovsk, Ukraine (I.B.); National Hospital Organization Osaka National Hospital, Osaka (N.M.), and Aichi Cancer Center Hospital, Nagoya (H.I.) - both in Japan; Istituto Europeo di Oncologia (M. Colleoni) and Pfizer Oncology (C.G.) - both in Milan; Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.), and Pfizer Oncology, Collegeville (C.H.B.) - both in Pennsylvania; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia (S. Loi); Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada (S.V.); Brustzentrum der Universität München, Munich (N.H.), and the German Breast Group, Neu-Isenburg (S. Loibl) - both in Germany; Institut Gustave Roussy, Villejuif, France (F.A.); Pfizer Oncology, Cambridge, MA (K.P.T.); and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Feinberg School of Medicine, Chicago (M. Cristofanilli).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1810527
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1810527DOI Listing
November 2018

Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.

Eur J Cancer 2018 03 3;92:1-10. Epub 2018 Feb 3.

Drug Development Department, Gustave Roussy, Department of Medical Oncology, Faculté de Medicine Paris-Sud XI, Kremlin-Bicêtre, France; Gustave Roussy Department of Medical Oncology, Faculté de Medicine Paris-Sud XI, Kremlin-Bicêtre, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.12.020DOI Listing
March 2018

Developing Anticancer Drugs in Orphan Molecular Entities - A Paradigm under Construction.

Authors:
Fabrice André

N Engl J Med 2018 02;378(8):763-765

From the Department of Medical Oncology, Institut Gustave Roussy, Université Paris Sud, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMe1716821DOI Listing
February 2018

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:
Shona Hendry Roberto Salgado Thomas Gevaert Prudence A Russell Tom John Bibhusal Thapa Michael Christie Koen van de Vijver M V Estrada Paula I Gonzalez-Ericsson Melinda Sanders Benjamin Solomon Cinzia Solinas Gert G G M Van den Eynden Yves Allory Matthias Preusser Johannes Hainfellner Giancarlo Pruneri Andrea Vingiani Sandra Demaria Fraser Symmans Paolo Nuciforo Laura Comerma E A Thompson Sunil Lakhani Seong-Rim Kim Stuart Schnitt Cecile Colpaert Christos Sotiriou Stefan J Scherer Michail Ignatiadis Sunil Badve Robert H Pierce Giuseppe Viale Nicolas Sirtaine Frederique Penault-Llorca Tomohagu Sugie Susan Fineberg Soonmyung Paik Ashok Srinivasan Andrea Richardson Yihong Wang Ewa Chmielik Jane Brock Douglas B Johnson Justin Balko Stephan Wienert Veerle Bossuyt Stefan Michiels Nils Ternes Nicole Burchardi Stephen J Luen Peter Savas Frederick Klauschen Peter H Watson Brad H Nelson Carmen Criscitiello Sandra O'Toole Denis Larsimont Roland de Wind Giuseppe Curigliano Fabrice André Magali Lacroix-Triki Mark van de Vijver Federico Rojo Giuseppe Floris Shahinaz Bedri Joseph Sparano David Rimm Torsten Nielsen Zuzana Kos Stephen Hewitt Baljit Singh Gelareh Farshid Sibylle Loibl Kimberly H Allison Nadine Tung Sylvia Adams Karen Willard-Gallo Hugo M Horlings Leena Gandhi Andre Moreira Fred Hirsch Maria V Dieci Maria Urbanowicz Iva Brcic Konstanty Korski Fabien Gaire Hartmut Koeppen Amy Lo Jennifer Giltnane Marlon C Rebelatto Keith E Steele Jiping Zha Kenneth Emancipator Jonathan W Juco Carsten Denkert Jorge Reis-Filho Sherene Loi Stephen B Fox

Adv Anat Pathol 2017 Nov;24(6):311-335

Departments of *Pathology §§§Medical Oncology, Peter MacCallum Cancer Centre, Melbourne †The Sir Peter MacCallum Department of Oncology Departments of **Pathology ∥∥Medicine, University of Melbourne ¶¶Department of Anatomical Pathology, Royal Melbourne Hospital, Parkville #Department of Anatomical Pathology, St Vincent's Hospital Melbourne, Fitzroy ††Department of Medical Oncology, Austin Health ‡‡Olivia Newton-John Cancer Research Institute, Heidelberg §§School of Cancer Medicine, La Trobe University, Bundoora §§§§§Centre for Clinical Research and School of Medicine, The University of Queensland ∥∥∥∥∥Pathology Queensland, Royal Brisbane and Women's Hospital, Brisbane §§§§§§§§§§The Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst ∥∥∥∥∥∥∥∥∥∥Australian Clinical Labs, Bella Vista ‡‡‡‡‡‡‡‡‡‡‡‡Directorate of Surgical Pathology, SA Pathology §§§§§§§§§§§§Discipline of Medicine, Adelaide University, Adelaide, Australia ***********Department of Surgical Oncology, Netherlands Cancer Institute †††††††††††††Department of Pathology ##Divisions of Diagnostic Oncology & Molecular Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands ###Université Paris-Est ****INSERM, UMR 955 ††††Département de pathologie, APHP, Hôpital Henri-Mondor, Créteil ∥∥∥∥∥∥∥∥∥Service de Biostatistique et d'Epidémiologie, Gustave Roussy, CESP, Inserm U1018, Université-Paris Sud, Université Paris-Saclay ¶¶¶¶¶¶¶¶¶¶INSERM Unit U981, and Department of Medical Oncology, Gustave Roussy, Villejuif ##########Faculté de Médecine, Université Paris Sud, Kremlin-Bicêtre †††††††Department of Surgical Pathology and Biopathology, Jean Perrin Comprehensive Cancer Centre ‡‡‡‡‡‡‡University of Auvergne UMR1240, Clermont-Ferrand, France ‡‡‡‡Department of Medicine, Clinical Division of Oncology §§§§Institute of Neurology, Comprehensive Cancer Centre Vienna, Medical University of Vienna, Vienna ††††††††††††††Institute of Pathology, Medical University of Graz, Austria ∥∥∥∥European Institute of Oncology ¶¶¶¶School of Medicine ######Department of Pathology, Istituto Europeo di Oncologia, University of Milan, Milan ¶¶¶¶¶¶¶¶¶¶¶¶¶Department of Surgery, Oncology and Gastroenterology, University of Padova #############Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy †††††Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona †††††††††††Pathology Department, IIS-Fundacion Jimenez Diaz, UAM, Madrid, Spain §Department of Pathology and TCRU, GZA ¶¶¶Department of Pathology, GZA Ziekenhuizen, Antwerp ∥Laboratory of Experimental Urology, Department of Development and Regeneration, KU Leuven ‡‡‡‡‡‡‡‡‡‡‡Department of Pathology, University Hospital Leuven, Leuven, Belgium ¶Department of Pathology, AZ Klina, Brasschaat ††††††Department of Pathology, GZA Ziekenhuizen, Sint-Augustinus, Wilrijk ∥∥∥Molecular Immunology Unit ‡‡‡‡‡‡Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles ‡Breast Cancer Translational Research Laboratory/Breast International Group, Institut Jules Bordet **************European Organisation for Research and Treatment of Cancer (EORTC) Headquarters *******Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium §§§§§§§Department of Surgery, Kansai Medical School, Hirakata, Japan #######Severance Biomedical Science Institute and Department of Medical Oncology, Yonsei University College of Medicine, Seoul, South Korea ∥∥∥∥∥∥∥∥Tumor Pathology Department, Maria Sklodowska-Curie Memorial Cancer Center ¶¶¶¶¶¶¶¶Institute of Oncology, Gliwice Branch, Gliwice, Poland ‡‡‡‡‡‡‡‡‡‡‡‡‡‡Pathology and Tissue Analytics, Roche Innovation Centre Munich, Penzberg †††††††††Institute of Pathology, Charité Universitätsmedizin Berlin ‡‡‡‡‡‡‡‡‡VMscope GmbH, Berlin ¶¶¶¶¶¶¶¶¶German Breast Group GmbH, Neu-Isenburg, Germany **********Trev & Joyce Deeley Research Centre, British Columbia Cancer Agency ††††††††††Department of Biochemistry and Microbiology, University of Victoria, Victoria Departments of ‡‡‡‡‡‡‡‡‡‡Medical Genetics #########Pathology and Laboratory Medicine ¶¶¶¶¶¶¶¶¶¶¶Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC ###########Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Canada §§§§§§§§§§§Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, Doha, Qatar ‡‡‡‡‡‡‡‡Department of Pathology and Laboratory Medicine, Rhode Island Hospital and Lifespan Medical Center §§§§§§§§Warren Alpert Medical School of Brown University, Providence ¶¶¶¶¶National Surgical Adjuvant Breast and Bowel Project Operations Center/NRG Oncology, Pittsburgh, PA †††Breast Cancer Research Program, Vanderbilt Ingram Cancer Center, Vanderbilt University Departments of ‡‡‡Pathology, Microbiology and Immunology ########Department of Medicine, Vanderbilt University Medical Centre *********Vanderbilt Ingram Cancer Center, Nashville §§§§§§§§§Department of Pathology, Yale University School of Medicine, New Haven ∥∥∥∥∥∥∥∥∥∥∥Department of Oncology, Montefiore Medical Centre, Albert Einstein College of Medicine ∥∥∥∥∥∥∥Montefiore Medical Center ¶¶¶¶¶¶¶The Albert Einstein College of Medicine, Bronx, NY ********Department of Pathology, Brigham and Women's Hospital #####Cancer Research Institute and Department of Pathology, Beth Israel Deaconess Cancer Center ******Harvard Medical School ¶¶¶¶¶¶¶¶¶¶¶¶Division of Hematology-Oncology, Beth Israel Deaconess Medical Center ††††††††Department of Cancer Biology ‡‡‡‡‡‡‡‡‡‡‡‡‡Dana-Farber Cancer Institute, Boston, MA ∥∥∥∥∥∥∥∥∥∥∥∥∥Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO ‡‡‡‡‡Department of Cancer Biology, Mayo Clinic, Jacksonville, FL ∥∥∥∥∥∥Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, IN ¶¶¶¶¶¶Cancer Immunotherapy Trials Network, Central Laboratory and Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA ††††††††††††Department of Pathology, New York University Langone Medical Centre ############New York University Medical School *************Perlmutter Cancer Center §§§§§§§§§§§§§Pulmonary Pathology, New York University Center for Biospecimen Research and Development, New York University ***************Department of Pathology, Memorial Sloan-Kettering Cancer Center ####Departments of Radiation Oncology and Pathology, Weill Cornell Medicine, New York, NY *****Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, TX ∥∥∥∥∥∥∥∥∥∥∥∥Pathology Department, Stanford University Medical Centre, Stanford ∥∥∥∥∥∥∥∥∥∥∥∥∥∥Department of Pathology, Stanford University, Palo Alto ***Department of Pathology, School of Medicine, University of California, San Diego §§§§§§§§§§§§§§Research Pathology, Genentech Inc., South San Francisco, CA *************Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda ¶¶¶¶¶¶¶¶¶¶¶¶¶¶Translational Sciences, MedImmune, Gaithersberg, MD §§§§§§Academic Medical Innovation, Novartis Pharmaceuticals Corporation, East Hanover ##############Translational Medicine, Merck & Co. Inc., Kenilworth, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAP.0000000000000161DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5638696PMC
November 2017

Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies.

Eur J Cancer 2017 11 19;86:257-265. Epub 2017 Oct 19.

Department of Medical, Surgery and Health Sciences, University of Trieste, Piazza Ospitale 1, 34129 Trieste, Italy; Breast Cancer Unit and Translational Research Unit, ASST Cremona, Viale Concordia 1, 26100 Cremona, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.09.018DOI Listing
November 2017

Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.

Authors:
Shona Hendry Roberto Salgado Thomas Gevaert Prudence A Russell Tom John Bibhusal Thapa Michael Christie Koen van de Vijver M V Estrada Paula I Gonzalez-Ericsson Melinda Sanders Benjamin Solomon Cinzia Solinas Gert G G M Van den Eynden Yves Allory Matthias Preusser Johannes Hainfellner Giancarlo Pruneri Andrea Vingiani Sandra Demaria Fraser Symmans Paolo Nuciforo Laura Comerma E A Thompson Sunil Lakhani Seong-Rim Kim Stuart Schnitt Cecile Colpaert Christos Sotiriou Stefan J Scherer Michail Ignatiadis Sunil Badve Robert H Pierce Giuseppe Viale Nicolas Sirtaine Frederique Penault-Llorca Tomohagu Sugie Susan Fineberg Soonmyung Paik Ashok Srinivasan Andrea Richardson Yihong Wang Ewa Chmielik Jane Brock Douglas B Johnson Justin Balko Stephan Wienert Veerle Bossuyt Stefan Michiels Nils Ternes Nicole Burchardi Stephen J Luen Peter Savas Frederick Klauschen Peter H Watson Brad H Nelson Carmen Criscitiello Sandra O'Toole Denis Larsimont Roland de Wind Giuseppe Curigliano Fabrice André Magali Lacroix-Triki Mark van de Vijver Federico Rojo Giuseppe Floris Shahinaz Bedri Joseph Sparano David Rimm Torsten Nielsen Zuzana Kos Stephen Hewitt Baljit Singh Gelareh Farshid Sibylle Loibl Kimberly H Allison Nadine Tung Sylvia Adams Karen Willard-Gallo Hugo M Horlings Leena Gandhi Andre Moreira Fred Hirsch Maria V Dieci Maria Urbanowicz Iva Brcic Konstanty Korski Fabien Gaire Hartmut Koeppen Amy Lo Jennifer Giltnane Marlon C Rebelatto Keith E Steele Jiping Zha Kenneth Emancipator Jonathan W Juco Carsten Denkert Jorge Reis-Filho Sherene Loi Stephen B Fox

Adv Anat Pathol 2017 Sep;24(5):235-251

Departments of *Pathology §§§Medical Oncology, Peter MacCallum Cancer Centre, Melbourne †The Sir Peter MacCallum Department of Oncology Departments of **Pathology ∥∥Medicine, University of Melbourne ¶¶Department of Anatomical Pathology, Royal Melbourne Hospital, Parkville #Department of Anatomical Pathology, St Vincent's Hospital Melbourne, Fitzroy ††Department of Medical Oncology, Austin Health ‡‡Olivia Newton-John Cancer Research Institute, Heidelberg §§School of Cancer Medicine, La Trobe University, Bundoora §§§§§Centre for Clinical Research and School of Medicine, The University of Queensland ∥∥∥∥∥Pathology Queensland, Royal Brisbane and Women's Hospital, Brisbane §§§§§§§§§§The Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst ∥∥∥∥∥∥∥∥∥∥Australian Clinical Labs, Bella Vista ‡‡‡‡‡‡‡‡‡‡‡‡Directorate of Surgical Pathology, SA Pathology §§§§§§§§§§§§Discipline of Medicine, Adelaide University, Adelaide, Australia ***********Department of Surgical Oncology, Netherlands Cancer Institute †††††††††††††Department of Pathology ##Divisions of Diagnostic Oncology & Molecular Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands ###Université Paris-Est ****INSERM, UMR 955 ††††Département de pathologie, APHP, Hôpital Henri-Mondor, Créteil ∥∥∥∥∥∥∥∥∥Service de Biostatistique et d'Epidémiologie, Gustave Roussy, CESP, Inserm U1018, Université-Paris Sud, Université Paris-Saclay ¶¶¶¶¶¶¶¶¶¶INSERM Unit U981, and Department of Medical Oncology, Gustave Roussy, Villejuif ##########Faculté de Médecine, Université Paris Sud, Kremlin-Bicêtre †††††††Department of Surgical Pathology and Biopathology, Jean Perrin Comprehensive Cancer Centre ‡‡‡‡‡‡‡University of Auvergne UMR1240, Clermont-Ferrand, France ‡‡‡‡Department of Medicine, Clinical Division of Oncology §§§§Institute of Neurology, Comprehensive Cancer Centre Vienna, Medical University of Vienna, Vienna ††††††††††††††Institute of Pathology, Medical University of Graz, Austria ∥∥∥∥European Institute of Oncology ¶¶¶¶School of Medicine ######Department of Pathology, Istituto Europeo di Oncologia, University of Milan, Milan ¶¶¶¶¶¶¶¶¶¶¶¶¶Department of Surgery, Oncology and Gastroenterology, University of Padova #############Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy †††††Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona †††††††††††Pathology Department, IIS-Fundacion Jimenez Diaz, UAM, Madrid, Spain §Department of Pathology and TCRU, GZA ¶¶¶Department of Pathology, GZA Ziekenhuizen, Antwerp ∥Laboratory of Experimental Urology, Department of Development and Regeneration, KU Leuven ‡‡‡‡‡‡‡‡‡‡‡Department of Pathology, University Hospital Leuven, Leuven, Belgium ¶Department of Pathology, AZ Klina, Brasschaat ††††††Department of Pathology, GZA Ziekenhuizen, Sint-Augustinus, Wilrijk ∥∥∥Molecular Immunology Unit ‡‡‡‡‡‡Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles ‡Breast Cancer Translational Research Laboratory/Breast International Group, Institut Jules Bordet **************European Organisation for Research and Treatment of Cancer (EORTC) Headquarters *******Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium §§§§§§§Department of Surgery, Kansai Medical School, Hirakata, Japan #######Severance Biomedical Science Institute and Department of Medical Oncology, Yonsei University College of Medicine, Seoul, South Korea ∥∥∥∥∥∥∥∥Tumor Pathology Department, Maria Sklodowska-Curie Memorial Cancer Center ¶¶¶¶¶¶¶¶Institute of Oncology, Gliwice Branch, Gliwice, Poland ‡‡‡‡‡‡‡‡‡‡‡‡‡‡Pathology and Tissue Analytics, Roche Innovation Centre Munich, Penzberg †††††††††Institute of Pathology, Charité Universitätsmedizin Berlin ‡‡‡‡‡‡‡‡‡VMscope GmbH, Berlin ¶¶¶¶¶¶¶¶¶German Breast Group GmbH, Neu-Isenburg, Germany **********Trev & Joyce Deeley Research Centre, British Columbia Cancer Agency ††††††††††Department of Biochemistry and Microbiology, University of Victoria, Victoria Departments of ‡‡‡‡‡‡‡‡‡‡Medical Genetics #########Pathology and Laboratory Medicine ¶¶¶¶¶¶¶¶¶¶¶Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC ###########Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Canada §§§§§§§§§§§Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, Doha, Qatar ‡‡‡‡‡‡‡‡Department of Pathology and Laboratory Medicine, Rhode Island Hospital and Lifespan Medical Center §§§§§§§§Warren Alpert Medical School of Brown University, Providence ¶¶¶¶¶National Surgical Adjuvant Breast and Bowel Project Operations Center/NRG Oncology, Pittsburgh, PA †††Breast Cancer Research Program, Vanderbilt Ingram Cancer Center, Vanderbilt University Departments of ‡‡‡Pathology, Microbiology and Immunology ########Department of Medicine, Vanderbilt University Medical Centre *********Vanderbilt Ingram Cancer Center, Nashville §§§§§§§§§Department of Pathology, Yale University School of Medicine, New Haven ∥∥∥∥∥∥∥∥∥∥∥Department of Oncology, Montefiore Medical Centre, Albert Einstein College of Medicine ∥∥∥∥∥∥∥Montefiore Medical Center ¶¶¶¶¶¶¶The Albert Einstein College of Medicine, Bronx, NY ********Department of Pathology, Brigham and Women's Hospital #####Cancer Research Institute and Department of Pathology, Beth Israel Deaconess Cancer Center ******Harvard Medical School ¶¶¶¶¶¶¶¶¶¶¶¶Division of Hematology-Oncology, Beth Israel Deaconess Medical Center ††††††††Department of Cancer Biology ‡‡‡‡‡‡‡‡‡‡‡‡‡Dana-Farber Cancer Institute, Boston, MA ∥∥∥∥∥∥∥∥∥∥∥∥∥Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO ‡‡‡‡‡Department of Cancer Biology, Mayo Clinic, Jacksonville, FL ∥∥∥∥∥∥Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, IN ¶¶¶¶¶¶Cancer Immunotherapy Trials Network, Central Laboratory and Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA ††††††††††††Department of Pathology, New York University Langone Medical Centre ############New York University Medical School *************Perlmutter Cancer Center §§§§§§§§§§§§§Pulmonary Pathology, New York University Center for Biospecimen Research and Development, New York University ***************Department of Pathology, Memorial Sloan-Kettering Cancer Center ####Departments of Radiation Oncology and Pathology, Weill Cornell Medicine, New York, NY *****Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, TX ∥∥∥∥∥∥∥∥∥∥∥∥Pathology Department, Stanford University Medical Centre, Stanford ∥∥∥∥∥∥∥∥∥∥∥∥∥∥Department of Pathology, Stanford University, Palo Alto ***Department of Pathology, School of Medicine, University of California, San Diego §§§§§§§§§§§§§§Research Pathology, Genentech Inc., South San Francisco, CA *************Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda ¶¶¶¶¶¶¶¶¶¶¶¶¶¶Translational Sciences, MedImmune, Gaithersberg, MD §§§§§§Academic Medical Innovation, Novartis Pharmaceuticals Corporation, East Hanover ##############Translational Medicine, Merck & Co. Inc., Kenilworth, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAP.0000000000000162DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564448PMC
September 2017

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update.

J Clin Oncol 2017 Aug 10;35(24):2838-2847. Epub 2017 Jul 10.

Ian Krop, Dana-Farber Cancer Institute, Boston, MA; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; Fabrice Andre, Institute Gustave Roussy, Paris, France; Robert C. Bast, The University of Texas MD Anderson Cancer Center, Houston; Robert G. Mennel, Baylor University Medical Center, Texas Oncology PA, Dallas, TX; William Barlow, Cancer Research and Biostatistics, Seattle, WA; Deborah E. Collyar, Patient Advocates in Research, Danville, CA; M. Elizabeth Hammond, University of Utah and Intermountain Health Care, Salt Lake City, UT; Nicole M. Kuderer, University of Washington Medical Center, Seattle, WA; Minetta C. Liu, Mayo Clinic College of Medicine, Rochester, MN; Catherine Van Poznak, University of Michigan, Ann Arbor, MI; and Antonio C. Wolff and Vered Stearns, Johns Hopkins University, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.0472DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846188PMC
August 2017

Advances in the treatment of advanced oestrogen-receptor-positive breast cancer.

Lancet 2017 Jun 7;389(10087):2403-2414. Epub 2016 Dec 7.

INSERM U981, Gustave Roussy Cancer Center, Université Paris Sud, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(16)32419-9DOI Listing
June 2017

Tumor-specific circulating angiogenic progenitors in breast and renal cell cancer: What prospects?

Eur J Cancer 2017 05 8;77:153-154. Epub 2017 Apr 8.

Department of Cancer Medicine, Gustave Roussy, Villejuif, France; Inserm U931, Cancer Biomarkers, Université Paris Saclay, Gustave Roussy, Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.03.016DOI Listing
May 2017

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.

J Clin Oncol 2017 Jan 21;35(2):157-165. Epub 2016 Nov 21.

Lucia Nogova, Reinhard Buettner, and Jürgen Wolf, University Hospital Cologne, Cologne; Martin Schuler, University Hospital Essen, and German Cancer Consortium (DKTK), Essen, Germany; Lecia V. Sequist, Massachusetts General Hospital; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Jose Manuel Perez Garcia, Vall d'Hebron Institut d'Oncologia, Barcelona; Manuel Hidalgo, Spanish National Cancer Research Centre, Madrid, Spain; Fabrice Andre, Gustave Roussy, Villejuif; Jean-Pierre Delord, Institute Universitaire du Cancer de Toulouse, Toulouse; Philippe A. Cassier, Centre Regional Leon-Berard, Lyon; Mario Campone, Institute de Cancerologie de l'Ouest-René Gauducheau, Nantes, France; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, and Utrecht University, Utrecht, the Netherlands; D. Ross Camidge, University of Colorado, Aurora, CO; Ulka Vaishampayan, Barbara Ann Karmanos Cancer Institute, Detroit, MI; Howard Burris, Sarah Cannon Research Institute, Nashville; G. Gary Tian, The West Clinic, Memphis, TN; Zev A. Wainberg, UCLA School of Medicine, Los Angeles, CA; Wan-Teck Lim, National Cancer Centre, Singapore; Patricia LoRusso, Yale Cancer Center, New Haven, CT; Katie Parker, Xueying Chen, Somesh Choudhury, and Randi Isaacs, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Dale Porter, Novartis Institutes for Biomedical Research, Cambridge, MA; Francois Ringeisen, Novartis Pharma AG; and Diana Graus-Porta, Novartis Institutes for Biomedical Research, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.2048DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6865065PMC
January 2017

A Systematic Evaluation of Blood Serum and Plasma Pre-Analytics for Metabolomics Cohort Studies.

Int J Mol Sci 2016 Dec 5;17(12). Epub 2016 Dec 5.

Centre Léon Bérard, Département de Recherche Translationnelle et de l'Innovation, Génomique des Cancers, 28 rue Laënnec, 69373 Lyon, CEDEX 08, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms17122035DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5187835PMC
December 2016

Reply to D.C. Sgroi et al, T. Sanft et al, M.S. Copur et al, and M.P. Goetz et al.

J Clin Oncol 2016 11;34(32):3946-3948

Lyndsay N. Harris, National Cancer Institute, Bethesda, MD; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; National Cancer Institute, Bethesda, MD; and Fabrice Andre, Institute Gustave Roussy, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.7020DOI Listing
November 2016

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

N Engl J Med 2016 11 7;375(18):1738-1748. Epub 2016 Oct 7.

From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1609709DOI Listing
November 2016

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.

J Clin Oncol 2016 09 6;34(25):2961-8. Epub 2016 Jun 6.

Charlotte Fribbens, Ben O'Leary, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Mitch Dowsett, and Nicholas C. Turner, Institute of Cancer Research; Charlotte Fribbens, Ben O'Leary, Stephen R.D. Johnston, and Nicholas C. Turner, Royal Marsden Hospital; Lucy Kilburn and Judith M. Bliss, The Institute of Cancer Research Clinical Trials and Statistics Unit, London, UK; Massimo Cristofanilli, Thomas Jefferson University, Philadelphia, PA; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Sherene Loi, University of Melbourne, Melbourne, Australia; Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and John Jiang, Cynthia Huang Bartlett, and Maria Koehler, Pfizer, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.3061DOI Listing
September 2016

The ratio of CD8/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma .

Oncoimmunology 2016 18;5(10):e1218106. Epub 2016 Aug 18.

Gustave Roussy Cancer Campus, Villejuif, France; INSERM, U1138, Paris, France; Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Center de Recherche des Cordeliers, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Université Pierre et Marie Curie, Paris, France; Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France; Karolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2016.1218106DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087306PMC
August 2016

Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial.

Clin Cancer Res 2016 06 12;22(12):2960-8. Epub 2016 Jan 12.

Laboratoire de Recherche Translationnelle et Centre de RessourcesBiologiques, AMMICA, INSERM US23/CNRS UMS3655, Gustave Roussy, Villejuif, France. INSERM U981, Gustave Roussy, Villejuif, France. Département de Biologie et Pathologie Médicales, Gustave Roussy, Villejuif, France. Faculté de Pharmacie, Université Paris Sud, Châtenay-Malabry, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-2470DOI Listing
June 2016

Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.

J Clin Oncol 2016 06 18;34(18):2115-24. Epub 2016 Apr 18.

Fabrice André, Institut Gustav Roussy, INSERM Unit U981, Université Paris Sud, Villejuif, France; Sara Hurvitz and Dennis Slamon, University of California, Los Angeles, Los Angeles, CA; Angelica Fasolo, San Raffaele Scientific Institute, Milan, Italy; Ling-Ming Tseng, National Yang Ming University, Taipei, Taiwan; Guy Jerusalem, University of Liège, Liege, Belgium; Sharon Wilks, Cancer Care Center of South Texas, San Antonio, TX; Ruth O'Regan, University of Wisconsin Carbone Cancer Center, Madison, WI; Claudine Isaacs, Georgetown University, Washington DC; Masakazu Toi, Kyoto University, Sakyo-ku, Kyoto, Japan; Howard Burris, Sarah Cannon Research Institute, Nashville, TN; Wei He, Douglas Robinson, and Markus Riester, Novartis Institutes for BioMedical Research, Cambridge, MA; and Tetiana Taran and David Chen, Novartis Pharmaceuticals Corporation, East Hanover, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.9161DOI Listing
June 2016

rCGH: a comprehensive array-based genomic profile platform for precision medicine.

Bioinformatics 2016 05 26;32(9):1402-4. Epub 2015 Dec 26.

INSERM U981, Gustave Roussy, University Paris-Sud, Villejuif 94805, France, Department of Medical Oncology, Gustave Roussy, Villejuif 94805, France.

View Article

Download full-text PDF

Source
https://academic.oup.com/bioinformatics/article-lookup/doi/1
Publisher Site
http://dx.doi.org/10.1093/bioinformatics/btv718DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848396PMC
May 2016

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

J Clin Oncol 2016 Apr 8;34(10):1134-50. Epub 2016 Feb 8.

Lyndsay N. Harris, Case Western Reserve University, Cleveland, OH; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; Lisa M. McShane, National Cancer Institute, Bethesda, MD; Fabrice Andre, Institute Gustave Roussy, Paris, France; Deborah E. Collyar, Patient Advocates in Research; Elizabeth H. Hammond, University of Utah and Intermountain Health Care, Salt Lake City, UT; Ana M. Gonzalez-Angulo and Robert C. Bast, The University of Texas MD Anderson Cancer Center, Houston; Robert G.Mennel, Baylor University Medical Center and Texas Oncology PA, Dallas, TX; Nicole M. Kuderer, University of Washington Medical Center, Seattle, WA; Minetta C. Liu, Mayo Clinic College of Medicine, Rochester, MN; and Catherine Van Poznak and Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2016/02/05/JCO.2015.65
Web Search
http://www.instituteforquality.org/sites/instituteforquality
Web Search
http://www.instituteforquality.org/sites/instituteforquality
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.65.2289
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.65.2289DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4933134PMC
April 2016

Precision medicine for metastatic breast cancer.

Am Soc Clin Oncol Educ Book 2015 :e2-7

From the Department of Medical Oncology, Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2015.35.e2DOI Listing
February 2016

Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor.

J Thorac Oncol 2016 Feb 18;11(2):e21-3. Epub 2015 Dec 18.

DITEP (Département d'Innovations Thérapeutiques et Essais Précoces), Gustave Roussy Cancer Campus, Villejuif, France; Faculté de médicine Paris-Sud XI, Kremlin-Bicêtre, France; U981 INSERM, Gustave Roussy Cancer Campus, Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2015.08.001DOI Listing
February 2016

Immunogenic cell death-related biomarkers: Impact on the survival of breast cancer patients after adjuvant chemotherapy.

Oncoimmunology 2016 Feb 31;5(2):e1082706. Epub 2015 Aug 31.

Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France; Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Center de Recherche des Cordeliers, Paris, France; INSERM, U1138, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Pôle de Biologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2015.1082706DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4801435PMC
February 2016

Precision medicine for metastatic breast cancer--limitations and solutions.

Nat Rev Clin Oncol 2015 Dec 21;12(12):693-704. Epub 2015 Jul 21.

Department of Medical Oncology, Gustave Roussy and Université Paris Sud, 94800 Villejuif, France.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrclinonc.2015.123
Publisher Site
http://dx.doi.org/10.1038/nrclinonc.2015.123DOI Listing
December 2015

What to expect from high throughput genomics in metastatic breast cancers?

Breast 2015 Nov 1;24 Suppl 2:S19-22. Epub 2015 Aug 1.

Institut National de la Santé et de la Recherche Médicale (INSERM) U981, Institut de cancérologie Gustave Roussy, Villejuif, F-94800, France; Department of Medical Oncology, Institut de cancérologie Gustave Roussy, Villejuif, F-94800, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2015.07.006DOI Listing
November 2015

Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1.

Science 2015 Nov 29;350(6263):972-8. Epub 2015 Oct 29.

Gustave Roussy Cancer Campus, Villejuif, France. INSERM, U1138, Paris, France. Équipe 11 Labellisée par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. Université Paris Descartes, Sorbonne Paris Cité, Paris, France. Université Pierre et Marie Curie, Paris, France. Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France. Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France. Karolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, 17176 Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/science.aad0779DOI Listing
November 2015

Predictive and Prognostic Value of the TauProtein in Breast Cancer.

Anticancer Res 2015 Oct;35(10):5179-84

Department of Breast and Gynaecological Surgery, Curie Institute, Versailles-St-Quentin-en-Yvelines University, Versailles, France EA 7285: "Clinics risks and security in women's health and perinatal health", Versailles-St-Quentin-en-Yvelines University, Versailles, France

View Article

Download full-text PDF

Source
October 2015

Natural and therapy-induced immunosurveillance in breast cancer.

Nat Med 2015 Oct;21(10):1128-38

Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm.3944DOI Listing
October 2015

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

N Engl J Med 2015 Jul 1;373(3):209-19. Epub 2015 Jun 1.

From Royal Marsden Hospital, London (N.C.T.); National Cancer Center, Goyang-si, South Korea (J.R.); Institut Gustave Roussy, Villejuif, France (F.A.); Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia (S. Loi); Sunnybrook Odette Cancer Centre, Toronto (S.V.); Aichi Cancer Center Hospital, Nagoya, Japan (H.I.); Brustzentrum der Universität München, Munich (N.H.), and German Breast Group Forschungs, Neu-Isenburg (S. Loibl) - both in Germany; Pfizer, New York (C.H.B., M.K.), La Jolla, CA (K.Z., S.R.), and Milan (C.G.); and Thomas Jefferson University, Philadelphia (M.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1505270DOI Listing
July 2015

Bevacizumab: the phoenix of breast oncology?

Lancet Oncol 2015 Jun 11;16(6):600-1. Epub 2015 May 11.

Department of Medical Oncology, Institut Bergonie, Bordeaux, France.

View Article

Download full-text PDF

Source
http://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(
Web Search
http://linkinghub.elsevier.com/retrieve/pii/S147020451570201
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(15)70201-9DOI Listing
June 2015

Targeted therapies for ER+/HER2- metastatic breast cancer.

BMC Med 2015 Jun 9;13:137. Epub 2015 Jun 9.

Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.

View Article

Download full-text PDF

Source
http://bmcmedicine.biomedcentral.com/articles/10.1186/s12916
Publisher Site
http://dx.doi.org/10.1186/s12916-015-0369-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462184PMC
June 2015

Targeting FGFR Signaling in Cancer.

Clin Cancer Res 2015 Jun;21(12):2684-94

Drug Development Department (DITEP), Gustave Roussy, Villejuif, France. University Paris Sud, INSERM U981, Predictive Biomarkers and New Therapeutic Strategies in Oncology, Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2329DOI Listing
June 2015

[Molecular signatures of breast cancer: What clinical utility?].

Bull Cancer 2015 Jun;102(6 Suppl 1):S102-5

Department of medical oncology, Institut Gustave-Roussy 114, rue Edouard-Vaillant, 94805 Villejuif cedex, France; Inserm U981, Institut Gustave-Roussy 114, rue Edouard-Vaillant, 94805 Villejuif cedex, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0007-4551(15)31227-3DOI Listing
June 2015

Ki67--no evidence for its use in node-positive breast cancer.

Nat Rev Clin Oncol 2015 May 17;12(5):296-301. Epub 2015 Mar 17.

Department of Medical Oncology, Gustave Roussy Institute, 114 rue E. Vaillant, 94800 Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2015.46DOI Listing
May 2015

Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.

J Clin Oncol 2015 Mar 22;33(9):983-91. Epub 2014 Dec 22.

Carsten Denkert, Bruno V. Sinn, Berit M. Pfitzner, Wolfgang D. Schmitt, Silvia Darb-Esfahan, Stephan Wienert, Frederick Klauschen, and Manfred Dietel, Charité Universitätsmedizin Berlin; Carsten Denkert, German Cancer Consortium (DKTK); Peter Klare, Praxisklinik and Breast Center; Jens-Uwe Blohmer, St Gertrauden Krankenhaus and Charité Universitätsmedizin; Micheal Untch, Helios Klinikum Berlin-Buch, Berlin; Gunter von Minckwitz, Stephan Gade, Keyur Mehta, and Sibylle Loibl, German Breast Group, Neu-Isenburg; Gunter von Minckwitz, Women's Hospital, University of Frankfurt; Hans Tesch, Bethanien Hospital, Frankfurt; Jan C. Brase, Ralf Kronenwett, Karin Fisch, and Kristin Krappmann, Sividon Diagnostics, Cologne; Ralf Kronenwett, Heinrich-Heine University Düsseldorf, Düsseldorf; Christian Schem, Christian-Albrechts Universität zu Kiel, Kiel; Christoph Salat, Onkologische Schwerpunktpraxis, Munich; Marcus Schmidt, Johannes-Gutenberg Universität Mainz, Mainz; Sherko Kümmel, Kliniken Essen-Mitte, Essen; Peter Sinn, University of Heidelberg, Heidelberg; Christian Jakisch and Sibylle Loibl, Sana Klinikum Offenbach, Offenbach; Toralf Reimer, Klinikum Südstadt, Rostock, Germany; Sherene Loi, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia; Sherene Loi and Christos Sotiriou, Institute Jules Bordet, Brussels, Belgium; and Fabrice André, Institute Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.58.1967DOI Listing
March 2015

Rationale for targeting fibroblast growth factor receptor signaling in breast cancer.

Breast Cancer Res Treat 2015 Feb 13;150(1):1-8. Epub 2015 Feb 13.

Institut Gustave-Roussy, 39 rue Camille Desmoulins, 94805, Villejuif, France,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-015-3301-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4344551PMC
February 2015

Personalized treatments of cancer patients: a reality in daily practice, a costly dream or a shared vision of the future from the oncology community?

Cancer Treat Rev 2014 Dec 17;40(10):1192-8. Epub 2014 Jul 17.

Department of Medicine, Gustave Roussy, Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2014.07.002DOI Listing
December 2014